51 1. Osaki M, Oshimura M, Ito H. Apoptosis (2004) 9, 667–676.

(1)

Bibliografia

50 BIBLIOGRAFIA

(2)

Bibliografia

51 1. Osaki M, Oshimura M, Ito H. Apoptosis (2004) 9, 667–676.

2. Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell.

Biol., 2010, 11, 329-341.

3. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC (November 1990).”Purification and characterization of phosphoinositide 3-kinase from rat liver”. J. Biol.Chem. 265 (32): 19704–11.

4. Pearce, L.R.; Komander, D.; Alessi, D.R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell. Biol., 2010, 9-22.

5. Wick, M.J.; Ramos, F.J.; Chen, H.; Quon, M.J.; Dong, L.Q.; Liu, F. Mouse 3- phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans- phosphorylation in the activation loop. J. Biol. Chem., 2003, 278, 42913-42919.

6. Mora, A.; Komander, D.; van Aalten, D.M.; Alessi, D.R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell. Dev. Biol., 2004, 15, 161- 170.

7. Zeng, X.; Xu,. H.; Glazer, R.I. Transformation of mammary epithelial cells by 3- phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res. 2002, 62, 3538-43.

8. Pearn, L.; Fisher, J.; Burnett, A.K.; Darley, R.L. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood., 2007, 109, 4461.

9. Ahmed, N.; Riley, C.; Quinn, M.A. An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br J. Cancer., 2008, 98, 1415-1424.

10. Alessi, D.R.; James, S.R.; Downes, C.P.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.;

Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol., 1997, 7, 261-269.

11. Carracedo, A.; Pandolfi, P.P. The PTEN-PI3K pathway: of feedbacks and cross- talks. Oncogene, 2008, 27, 5527-5541.

12. WILLIAMS RL AND KATAN M. Structural views of phosphoinositidespecific phospholipase C: signalling the way ahead. Structure 4: 1387–1394, 1996.

13. Sekiya, F., Poulin, B., Kim, Y. J. and Rhee, S. G. (2004). Mechanism of tyrosine

phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 Journal

ofphosphorylation is not sufficient for lipase activation. J Biol Chem 279, 32181-

32190.

(3)

Bibliografia

52 14. Burden-Gulley SM, Gates TJ, Burgoyne AM, Cutter JL, Lodowski D, Robinson S, Sloan AE, Miller RH, Basilion JP, Brady-Kalnay SM. Un romanzo molecolare diagnostica dei glioblastomi: Rilevamento di un frammento extracellulare di PTPmu. Neoplasia. 2010; 4: 305-16.

15. Burgoyne AM, Palomo JM, Phillips-Mason PJ, Burden-Gulley SM, il maggiore DL, Zaremba A, Robinson S, Sloan AE, Vogelbaum MA, RH Miller, Brady-Kalnay SM.

PTPmu sopprime la migrazione delle cellule di glioma e di dispersione.

NeuroOncol. 2009a; 11: 767-778.

16. Carpenter, G., and Ji, Q. (1999) Exp. Cell Res. 253, 15–24.

17. Wells A, Grandis JR. Phospholipase C-g1 in tumor progression. Clin Exp Metastasis 2003; 20: 285–90.

18. Yamaguchi H, Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Bioch Byophys Acta 2007; 1773: 642–652.

19. Sala, G., Dituri, F., Raimondi, C., Previdi, S., Maffucci, T., Mazzoletti, M., Rossi, C., Iezzi, M., Lattanzio, R., Piantelli, M. et al. (2008). Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res 68, 10187-10196.

20. Liu, Y., Wang, J., Wu, M., Wan, W., Sun, R., Yang, D., Sun, X., Ma, D., Ying, G.

and Zhang, N. (2009). Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 7, 944-954.

21. Kassis, J., Moellinger, J., Lo, H., Greenberg, N. M., Kim, H. G. and Wells, A.

(1999). A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 5, 2251-2260.

22. Falasca, M.; Chiozzotto, D.; Godage, H.Y.; Mazzoletti, M.; Riley, A.M.; Previdi, S.;

Potter, B.V.; Broggini, M.; Maffucci, T. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br. J. Cancer, 2010, 102, 104-114.

23. Komander, D.; Fairservice, A.; Deak, M.; Kular, G.S.; Prescott, A.R.; Peter Downes, C.; Safrany, S.T.; Alessi, D.R.; van Aalten, D.M. Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. Embo J., 2004, 23, 3918-3928.

24. K.Nagashima et al. (2011). Genetic and pharmacological inhibition of PDK1 in

cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol

Chem, 286, 6433-6448.

(4)

Bibliografia

53 25. Ellershaw DC, Greenwood IA, Large WA (2002). Modulation of volume-sensitive chloride current by noradrenaline in rabbit portal vein myocytes. J Physiol 542:

537–547.

26. Kim TW, Koh SD, Ordög T, Ward SM, Sanders KM (2003). Muscarinic regulation of pacemaker frequency in murine gastric interstitial cells of Cajal. J Physiol 546:

415–425.

27. Yule DI, Williams JA (1992). U73122 inhibits Ca2+ oscillations in response to cholecystokinin and carbachol but not to JMV-180 in rat pancreatic acinar cells. J Biol Chem 267: 13830–13835.

28. Baselga J. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine. December 2011.

29. Vasudevan, K.M.; Barbie, D.A.; Davies, M.A.; Rabinovsky, R.; McNear, C.J.; Kim, J.J.; Hennessy, B.T.; Tseng, H.; Pochanard, P.; Kim, S.Y.; Dunn, I.F.; Schinzel, A.C.; Sandy, P.; Hoersch, S.; Sheng, Q.; Gupta, P.B.; Boehm, J.S.; Reiling, J.H.;

Silver, S.; Lu, Y.; Stemke-Hale, K.; Dutta, B.; Joy, C.; Sahin, A.A.; Gonzalez-

Angulo, A.M.; Lluch, A.; Rameh, L.E.; Jacks, T.; Root, D.E.; Lander, E.S.; Mills,

G.B.; Hahn, W.C.; Sellers, W.R.; Garraway, L.A. AKT-independent signaling

downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell., 2009,

16, 21-32.